节点文献

甲状腺功能亢进131Ⅰ治疗前后骨密度测定的临床分析

Clinical analysis of bone mineral density in patients of GD before and after 131Ⅰ therapy

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 佘立群廖国荣邹德环朱旭生

【Author】 She Liqun,Liao Guorong,Zou Dehuan,et al.Department of Nuclear Medicine,the First Municipal People’s Hospital of Guangzhou,Guangzhou 510180,China

【机构】 广州市第一人民医院核医学科广州市第一人民医院核医学科 510180510180510180

【摘要】 目的 探讨甲亢患者13 1Ⅰ治疗前后临床缓解持续时间的长短及其骨密度的变化情况。方法  70例甲亢患者于13 1Ⅰ治疗前和其中 37例于13 1Ⅰ治疗后临床缓解小于 6个月、 9~ 12个月和大于 18个月分别用双能X线骨密度仪 (DEXA)进行骨密度 (BMD)测定 ,并分别与年龄匹配正常健康者 95例进行对照分析。结果 ①甲亢13 1Ⅰ治疗前和治疗后临床缓解早、中期L2 4BMD均明显低于正常对照组 ,差异有非常显著性 ,Ward’s区虽低于正常对照组 ,但差异无显著性 ;②13 1Ⅰ治疗后临床缓解后期L2 4及Ward’s区的BMD改善至接近正常人水平 ,差异无显著性 ;③13 1I治疗后临床甲低组L2 4及Ward’s区的BMD均明显低于正常对照组 ,差异有非常显著性。结论 甲亢经13 1Ⅰ治疗后临床缓解早、中期骨矿含量改善不明显 ,至后期逐渐增加接近正常对照组水平 ;13 1Ⅰ治疗后临床甲低持续时间大于 6个月者 ,同样会导致骨矿含量的降低。

【Abstract】 Objective To investigate the change of bone mineral density (BMD) in patients with Graves’ disease (GD) before 131 Ⅰ therapy and clinical released duration length after 131 Ⅰ therapy. Methods By detecting the value of BMD in lumbar vertebyae (L 2-4 ),Ward’s triangular zone in 70 patients with GD before 131 Ⅰ therapy using dual-energy X-ray absorptionmery (DEXA),and BMDs were measured respectively in thirty-seven of them in the time of clinical released less than 6 months,9-12months and longer than 18 months after 131 Ⅰ therapy.The result was also compared with the value of BMD in 95 cases healthy with the age and sex matched. Results (1)The BMD of L 2-4 which in the group of GD before 131 Ⅰ therapy and in the early or middle stage after 131 Ⅰ therapy was obviously lower than the control group.There was very clear difference between them.No significant difference in Ward’s BMD was found between them.(2)The improvement of L 2-4 and Ward’s BMD,which in the last stage of clinical released after 131 Ⅰ therapy,was approach to the normal level,and there was no clear difference.(3)The BMD of L 2-4 and Ward’s in the group of clinical hypothyroidism was significantly lower compared with that of control group. Conclusion The improvement of BMD was unclearly,in which the group of GD before 131 Ⅰ therapy and in the early or middle stage after 131 Ⅰ therapy.And it would increase to approaching the level of control group in the last stage of clinical released after 131 Ⅰ therapy gradually.The duration which more than 6 months in the patients with clinical hypothyroidism after 131 Ⅰ therapy also result in the decrease in BMD.

  • 【文献出处】 广州医药 ,Guangzhou Medical Journal , 编辑部邮箱 ,2004年03期
  • 【分类号】R581.1
  • 【下载频次】54
节点文献中: 

本文链接的文献网络图示:

本文的引文网络